A fully integrated, global biotech with the spirit of a start-up, Ichnos Sciences is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology, autoimmune disease and pain. The Company, with headquarters in Paramus, N.J., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and treat patients holistically. With a patented BEAT® technology platform along with pioneering teams in Switzerland and India, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will hopefully extend and improve lives, writing a new chapter in healthcare.
Inspired by nature and building on past scientific advancements, we developed our novel, patented BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) platform to deliver new therapies. Combined with our disease-centric approach, the BEAT platform has the potential to deliver significant progress in some of the most challenging therapeutic areas of oncology.
We’re also working to deliver novel therapies for autoimmune diseases. With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block a key immune system activation factor, OX40, to potentially reduce the immune system’s auto-reactive responses.